First Time Loading...

Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 1.33 USD -2.92%
Updated: Apr 26, 2024

Intrinsic Value

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. [ Read More ]

The intrinsic value of one AKBA stock under the Base Case scenario is 3.34 USD. Compared to the current market price of 1.33 USD, Akebia Therapeutics Inc is Undervalued by 60%.

Key Points:
AKBA Intrinsic Value
Base Case
3.34 USD
Undervaluation 60%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Akebia Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AKBA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Akebia Therapeutics Inc

Provide an overview of the primary business activities
of Akebia Therapeutics Inc.

What unique competitive advantages
does Akebia Therapeutics Inc hold over its rivals?

What risks and challenges
does Akebia Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Akebia Therapeutics Inc recently?

Summarize the latest earnings call
of Akebia Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Akebia Therapeutics Inc.

Provide P/S
for Akebia Therapeutics Inc.

Provide P/E
for Akebia Therapeutics Inc.

Provide P/OCF
for Akebia Therapeutics Inc.

Provide P/FCFE
for Akebia Therapeutics Inc.

Provide P/B
for Akebia Therapeutics Inc.

Provide EV/S
for Akebia Therapeutics Inc.

Provide EV/GP
for Akebia Therapeutics Inc.

Provide EV/EBITDA
for Akebia Therapeutics Inc.

Provide EV/EBIT
for Akebia Therapeutics Inc.

Provide EV/OCF
for Akebia Therapeutics Inc.

Provide EV/FCFF
for Akebia Therapeutics Inc.

Provide EV/IC
for Akebia Therapeutics Inc.

Show me price targets
for Akebia Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Akebia Therapeutics Inc?

How accurate were the past Revenue estimates
for Akebia Therapeutics Inc?

What are the Net Income projections
for Akebia Therapeutics Inc?

How accurate were the past Net Income estimates
for Akebia Therapeutics Inc?

What are the EPS projections
for Akebia Therapeutics Inc?

How accurate were the past EPS estimates
for Akebia Therapeutics Inc?

What are the EBIT projections
for Akebia Therapeutics Inc?

How accurate were the past EBIT estimates
for Akebia Therapeutics Inc?

Compare the revenue forecasts
for Akebia Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Akebia Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Akebia Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Akebia Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Akebia Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Akebia Therapeutics Inc with its peers.

Analyze the financial leverage
of Akebia Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Akebia Therapeutics Inc.

Provide ROE
for Akebia Therapeutics Inc.

Provide ROA
for Akebia Therapeutics Inc.

Provide ROIC
for Akebia Therapeutics Inc.

Provide ROCE
for Akebia Therapeutics Inc.

Provide Gross Margin
for Akebia Therapeutics Inc.

Provide Operating Margin
for Akebia Therapeutics Inc.

Provide Net Margin
for Akebia Therapeutics Inc.

Provide FCF Margin
for Akebia Therapeutics Inc.

Show all solvency ratios
for Akebia Therapeutics Inc.

Provide D/E Ratio
for Akebia Therapeutics Inc.

Provide D/A Ratio
for Akebia Therapeutics Inc.

Provide Interest Coverage Ratio
for Akebia Therapeutics Inc.

Provide Altman Z-Score Ratio
for Akebia Therapeutics Inc.

Provide Quick Ratio
for Akebia Therapeutics Inc.

Provide Current Ratio
for Akebia Therapeutics Inc.

Provide Cash Ratio
for Akebia Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Akebia Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Akebia Therapeutics Inc?

What is the current Free Cash Flow
of Akebia Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Akebia Therapeutics Inc.

Financials

Balance Sheet Decomposition
Akebia Therapeutics Inc

Current Assets 118.1m
Cash & Short-Term Investments 42.9m
Receivables 39.3m
Other Current Assets 35.9m
Non-Current Assets 123.6m
PP&E 16m
Intangibles 95.1m
Other Non-Current Assets 12.4m
Current Liabilities 99.9m
Accounts Payable 14.6m
Accrued Liabilities 67.7m
Other Current Liabilities 17.5m
Non-Current Liabilities 172.4m
Long-Term Debt 17.2m
Other Non-Current Liabilities 155.2m
Efficiency

Earnings Waterfall
Akebia Therapeutics Inc

Revenue
194.6m USD
Cost of Revenue
-39.7m USD
Gross Profit
154.9m USD
Operating Expenses
-199.4m USD
Operating Income
-44.5m USD
Other Expenses
-7.5m USD
Net Income
-51.9m USD

Free Cash Flow Analysis
Akebia Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

AKBA Profitability Score
Profitability Due Diligence

Akebia Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

30/100
Profitability
Score

Akebia Therapeutics Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

AKBA Solvency Score
Solvency Due Diligence

Akebia Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Short-Term Solvency
Long-Term Solvency
39/100
Solvency
Score

Akebia Therapeutics Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AKBA Price Targets Summary
Akebia Therapeutics Inc

Wall Street analysts forecast AKBA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AKBA is 5.1 USD with a low forecast of 4.04 USD and a high forecast of 6.3 USD.

Lowest
Price Target
4.04 USD
204% Upside
Average
Price Target
5.1 USD
283% Upside
Highest
Price Target
6.3 USD
374% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AKBA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AKBA Price
Akebia Therapeutics Inc

1M 1M
-34%
6M 6M
+62%
1Y 1Y
+68%
3Y 3Y
-58%
5Y 5Y
-79%
10Y 10Y
-94%
Annual Price Range
1.33
52w Low
0.79
52w High
2.24
Price Metrics
Average Annual Return -36.33%
Standard Deviation of Annual Returns 33.96%
Max Drawdown -98%
Shares Statistics
Market Capitalization 258.8m USD
Shares Outstanding 209 372 000
Percentage of Shares Shorted 6.47%

AKBA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

258.8m USD

Dividend Yield

0%

Description

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

Contact

MASSACHUSETTS
Cambridge
245 1st St
+16178712098.0
https://akebia.com/

IPO

2014-03-20

Employees

426

Officers

CEO, President, Interim Principal Financial Officer & Director
Mr. John P. Butler MBA
Senior VP & COO
Mr. Michel Dahan
Senior VP, Chief Legal Officer & Secretary
Ms. Nicole R. Hadas J.D.
Senior VP of Research & Development and Chief Medical Officer
Dr. Steven Keith Burke M.D.
Chief Accounting Officer
Mr. Richard C. Malabre
Senior VP & Chief Technical Officer
Ms. Kimberly Garko
Show More
Vice President of Portfolio Strategy & Corporate Administration
Tracey Vetterick
Director of Corporate Communications
Mercedes Carrasco
Senior VP & Chief People Officer
Ms. Meredith Bowman
Senior Vice President of Legal & General Counsel
Ms. Carolyn Rucci
Show Less

See Also

Discover More
What is the Intrinsic Value of one AKBA stock?

The intrinsic value of one AKBA stock under the Base Case scenario is 3.34 USD.

Is AKBA stock undervalued or overvalued?

Compared to the current market price of 1.33 USD, Akebia Therapeutics Inc is Undervalued by 60%.